Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 21, Issue 1, Pages 13-20Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.beha.2007.11.003
Keywords
FLT3 inhibitors; resistance; staurosporine; midostaurin; PKC412; tandutinib; MLN 518; lestaurtinib; CEP701; SU11248; AML
Categories
Funding
- Howard Hughes Medical Institute Funding Source: Medline
Ask authors/readers for more resources
The identification of FLT3 mutations across a range of the cytogenetic subgroups of AML has opened up the possibility of a targeted therapeutic approach with broad applicability. Four agents are currently in clinical trials, at least 3 of which have both sufficient activity against AML and sufficiently acceptable toxicity profiles to support continued efforts to refine their inclusion into therapeutic regimens for AML. Better understanding of the genetics of inherent and acquired resistance is needed to guide development of second-generation agents. Optimizing the integration of FLT3 inhibitor therapy with chemotherapy has the potential both to decrease toxicity and improve response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available